TBT Pharma

TBT Pharma is a private clinical-stage dermatology company developing low-cost topical therapies for inflammatory and stress-related skin disorders. The company focuses on repurposing time-tested, FDA-approved drugs for topical administration, with the goal of replacing topical steroids as first-line treatment in selected indications. Its lead disclosed program, TBT-101, is positioned for psoriasis, keloids, alopecia areata, and other inflammatory skin conditions, while TBT-102 is described as a topical cosmeceutical candidate for wrinkles and skin thinning. TBT Pharma states that its approach is based on discoveries linking local stress hormone production in skin to disease biology, and it has cited exclusive patent licenses from NYU and Northwestern. The company appears to be a small, privately held U.S. dermatology biotech led by founder and CEO Ian Tolfree.